CLINICAL TRIAL: A DOUBLE BLIND, PLACEBO CONTROLLED, PHASE II, RANDOMIZED STUDY O

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这项研究将观察一种名为洛伐他汀的药物在治疗轻度活动型类风湿性关节炎(RA)患者中的效果。洛伐他汀是FDA批准用于治疗高胆固醇的他汀类药物之一，但目前未被批准用于治疗RA。实验室研究表明，洛伐他汀对轻度活动型类风湿关节炎的治疗可能是有益的。这项研究的目的之一是确定洛伐他汀在减轻轻度活动期RA患者的炎症方面是否有效。另一个目的是观察对轻度活动型类风湿关节炎的治疗是否安全。这项研究将通过比较接受研究药物洛伐他汀的RA患者和没有接受研究药物洛伐他汀的患者来观察洛伐他汀的效果。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study will look at the effects of a drug called lovastatin in the treatment of patients with mildly active rheumatoid arthritis (RA). Lovastatin is one of the statin drugs approved by the FDA for the treatment of high cholesterol, but it is currently not approved for treating RA. There is evidence from laboratory studies that lovastatin may be beneficial in the treatment of mildly active RA. One purpose of this study is to determine if lovastatin is effective in reducing the inflammation that is seen in patients with mildly active RA. Another purpose is to see if it safe for treatment of mildly active RA. This study will look at the effects of lovastatin by comparing subjects with RA who are receiving the study drug, lovastatin, to those who do not.